Generics - Generics, Ranbaxy Laboratories

Filter

Popular Filters

1 to 25 of 47 results

Sun Pharma’s takeover of Ranbaxy comes to attention of Competition Commission

Sun Pharma’s takeover of Ranbaxy comes to attention of Competition Commission

11-08-2014

The deal between Indian generics company Sun Pharmaceutical Industries which acquired fellow Indian drug…

CCIGenericsIndiaMergers & AcquisitionsPharmaceuticalRanbaxy LaboratoriesSun Pharmaceutical Industries

Ranbaxy down on same quarter last year following FDA fine

Ranbaxy down on same quarter last year following FDA fine

30-07-2014

Indian generic pharma company Ranbaxy, has reported consolidated sales of 23.7 billion rupees ($394 million),…

BSE SensexFinancialGenericsIndiaOver-the-counter accountingPharmaceutical industryRanbaxyRanbaxy Laboratories

Sun Pharma acquires Pharmalucence

Sun Pharma acquires Pharmalucence

16-07-2014

Sun Pharmaceutical Industries, India's third-largest generic drugmaker by sales, revealed that it has…

BSE SensexEconomy of IndiaGenericsIndiaMergers & AcquisitionsPharmalucenceProductionRanbaxy LaboratoriesSun Pharmaceuticals

US regulatory warnings on drug producers extend well beyond India

US regulatory warnings on drug producers extend well beyond India

14-07-2014

Hauled up by the US Food and Drug Administration for product recalls and quality issues, Indian pharmaceutical…

CiplaDr Reddy's LaboratoriesGenericsIndiaLupinProductionRanbaxy LaboratoriesRegulationSun PharmaceuticalUSA

Ranbaxy’s Toansa plant assessment concluded: no risk to public health, EU view

Ranbaxy’s Toansa plant assessment concluded: no risk to public health, EU view

05-06-2014

European regulatory authorities have finalized their assessment of reported non-compliance with Good…

EuropeGenericsIndiaProductionRanbaxy LaboratoriesRegulation

Indian court ruling lifts temporary stay on Sun Pharma takeover of Ranbaxy

26-05-2014

Indian generics drugmaker Sun Pharmaceuticals’ proposed $3.2 billion acquisition of loss-making rival…

Daiichi SankyoGenericsLegalMergers & AcquisitionsRanbaxy LaboratoriesSun Pharmaceuticals

Sun Pharma vows “appropriate action” as Ranbaxy merger halted

05-05-2014

In the wake of a suspension of its proposed $4 billion acquisition of domestic rival Ranbaxy Laboratories…

GenericsIndiaMergers & AcquisitionsProductionRanbaxy LaboratoriesSun Pharmaceutical IndustriesUSA

Troubled Ranbaxy to be acquired by Sun Pharma for around $4 billion

Troubled Ranbaxy to be acquired by Sun Pharma for around $4 billion

07-04-2014

In something of a surprise announcement, Sun Pharmaceutical Industries revealed this morning that it…

Daiichi SankyoGenericsIndiaMergers & AcquisitionsRanbaxy LaboratoriesSun Pharmaceuticals

Ranbaxy temporarily suspends shipments from Toansa and Dewas plants

25-02-2014

Indian drugmaker Ranbaxy Laboratories has announced in a letter to the Stock Exchange that it has temporarily…

Asia-PacificDaiichi SankyoGenericsIndiaProductionRanbaxy Laboratories

Ranbaxy rises on 4th-qtr performance, but can this continue?

Ranbaxy rises on 4th-qtr performance, but can this continue?

05-02-2014

Ranbaxy Laboratories, India’s largest generic drugmaker by sales, saw its shares rise 5.6% to 340 rupees…

Daiichi SankyoFinancialGenericsRanbaxy Laboratories

Another ban by US FDA on a Ranbaxy production facility

Another ban by US FDA on a Ranbaxy production facility

24-01-2014

As if the Indian drug major has not had enough negative news from the US regulator, the US Food and Drug…

Asia-PacificDaiichi SankyoGenericsIndiaNorth AmericaProductionRanbaxy LaboratoriesRegulationUSA

Ranbaxy cleared to market branded generic of Aricept in Canada

Ranbaxy cleared to market branded generic of Aricept in Canada

08-01-2014

The Canadian subsidiary of Ranbaxy Laboratories has received approval to manufacture and market RAN-Donepezil…

AriceptCanadaDaiichi SankyoEisaiGenericsNeurologicalNorth AmericaRAN-DonepezilRanbaxy LaboratoriesRegulation

Ban on FDA-regulated drugs from Ranbaxy's Mohali plant

17-09-2013

There was another blow for India's largest drugmaker Ranbaxy Laboratories (BSE: 500359) yesterday (September…

Asia-PacificDaiichi SankyoGenericsNorth AmericaProductionRanbaxy LaboratoriesRegulation

Ranbaxy 2nd-qtr sales fall 18%; reports loss

08-08-2013

India's largest drugmaker Ranbaxy Laboratories (BSE: 500359) reported second-quarter 2013 financial results,…

FinancialGenericsRanbaxy Laboratories

Leading Indian drugmakers eye pharma production in Russia

08-07-2013

Several top Indian drugmakers and suppliers, including Dr Reddy's (NYSE: RDY), Ranbaxy (BSE: 500359),…

Asia-PacificAurobindo PharmaCiplaDr Reddy's LaboratoriesEuropeGenericsProductionRanbaxy Laboratories

EU Commission fines Lundbeck and other Pharmas over "pay-for-delay" deals

19-06-2013

In a much awaited decision following its investigations of patent settlements (or pay-for-delay deals)…

ActaviscitalopramEuropeFinancialGenericsLegalLundbeckMerck KGaAMylan LaboratoriesNeurologicalPatentsPharmaceuticalRanbaxy Laboratories

Ranbaxy highlights its actions on improved business and quality assurance

23-05-2013

Indian drugmaker Ranbaxy Laboratories (BSE: 500359), whose US subsidiary was the subject of the biggest…

Daiichi SankyoGenericsManagementProductionRanbaxy LaboratoriesRegulation

US DoJ says Ranbaxy pleads guilty and agrees to pay $500 million in settlements

14-05-2013

In the largest drug safety settlement to date with a generic drug manufacturer, Ranbaxy USA, a subsidiary…

Asia-PacificDaiichi SankyoFinancialGenericsLegalNorth AmericaProductionRanbaxy LaboratoriesRegulation

Ranbaxy 1st-qtr 2013 earnings plunge 90% as sales fall 34%

08-05-2013

India's largest pharma company Ranbaxy Laboratories (BSE: 500359), which is majority owned by Japan's…

FinancialGenericsRanbaxy Laboratories

Daiichi Sankyo and Ranbaxy to launch branded generics in Brazil

21-04-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) and its majority (64%)-owned Indian affiliate Ranbaxy…

Daiichi SankyoGenericsMarkets & MarketingPharmaceuticalRanbaxy LaboratoriesSouth America

Ranbaxy in deal with Alembic to market bioequivalent Pristiq in USA

05-03-2013

The US subsidiary of India's largest drugmaker, Ranbaxy Laboratories (AB: BO), which is majority owned…

Alembic PharmaceuticalsDaiichi SankyoGenericsLicensingMarkets & MarketingNeurologicalNorth AmericaPatentsPfizerPristiqRanbaxy Laboratories

India's Ranbaxy posts 23% sales growth for 2012

26-02-2013

India's largest drugmaker Ranbaxy Laboratories (AB: BO) yesterday reported financial results for 2012,…

FinancialGenericsRanbaxy Laboratories

1 to 25 of 47 results

Back to top